Swiss dental technology company vVardis Holding has raised $175 million through its US initial public offering, selling approximately 9.7 million shares at $18 each. The final price came below the proposed range of $21 to $24 per share, while the company increased the number of shares offered compared with its most recent revised plan.

The offering marks the company’s entry into the US public markets as it seeks to expand the visibility of its proprietary, non-invasive dental treatments for early-stage cavities.

IPO Pricing and Offering Structure

vVardis initially planned to offer 8.3 million shares before pricing the IPO at 9.7 million shares. The company had previously reduced its proposed offering from 9.5 million shares on November 12, making the final share count higher than the most recent revised plan.

Despite offering more shares, vVardis priced the IPO at $18, below the initial $21 to $24 price range. The transaction generated approximately $175 million in gross proceeds.

The company will trade on the New York Stock Exchange under the ticker symbol VVVV. Goldman Sachs, J.P. Morgan, William Blair, UBS Investment Bank, and Deutsche Bank acted as joint bookrunners.

Curodont Product Portfolio

Based in Zug, Switzerland, vVardis develops and sells Curodont, a peptide-based treatment designed to address early-stage cavities without conventional drilling or needles. The treatment is applied in a dental office in five minutes or less, offering a non-invasive approach to early cavity management.

Its US product, Curodont Repair Fluoride Plus, is marketed as an over-the-counter drug under an FDA monograph and generates the vast majority of the company’s revenue.

The company also sells Curodont Repair, a fluoride-free version classified as a medical device in the United Kingdom and parts of Europe. The two products form the core of vVardis’ commercial offering across its markets.

Market Position and Commercial Focus

vVardis operates in the dental care market with a product portfolio focused on non-invasive treatment options. Its commercial model is built around proprietary peptide-based technology and products intended for early-stage cavity treatment.

The company’s dependence on Curodont Repair Fluoride Plus is an important consideration for investors, as the US product accounts for the vast majority of revenue. Its ability to maintain and expand commercial adoption across markets will be relevant to its performance as a newly listed company.

Closing Insights

vVardis’ $175 million IPO provides the Swiss company with public-market access, although its final pricing below the proposed range indicates that the shares were offered at a lower valuation than initially targeted. The increase in shares offered helped generate the stated proceeds despite the lower per-share price.

Investor attention will now turn to the company’s commercial performance, particularly the adoption of Curodont Repair Fluoride Plus in the United States and the expansion of its non-invasive dental treatment portfolio in international markets.